½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1422958

G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå : Á¦Ç°º°, ºÐ¼® À¯Çüº°, ¿ëµµº°, Áö¿ªº°(2024-2032³â)

G-Protein Coupled Receptors Market by Product, Assay Type, Application, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 140 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå ±Ô¸ð´Â 2023³â 34¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024³âºÎÅÍ 2032³â±îÁö 5.69%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 2032³â±îÁö 57¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇÏ°í ÀÖ½À´Ï´Ù. ½Å¾à °³¹ß¿¡¼­ GPCRÀÇ Ã¤Åà Áõ°¡, ¾Ï ȯÀÚ ¼ö Áõ°¡, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) È°µ¿Àº ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR)´Â Àΰ£ °Ô³ð¿¡ ¾ÏȣȭµÇ¾î ÀÖ´Â °¡Àå Å« ´Ü¹éÁú ±ºÀ¸·Î, ¼¼Æ÷¿¡ ½ÅÈ£¸¦ Àü´ÞÇÏ´Â ½ÅÈ£ Àü´Þ ºÐÀÚ·Î ¼¼Æ÷ ¿ÜºÎÀÇ ÀÚ±ØÀ» ¼¼Æ÷ ³» ¹ÝÀÀÀ¸·Î ÀüȯÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¼¼Æ÷¸·¿¡ Á¸ÀçÇÏ°í ¸ðµç »ý¸®Àû °úÁ¤¿¡ °ü¿©ÇÑ´Ù, GPCRÀº ¼¼Æ÷ Ç¥¸éÀÇ ¼ö¿ëü·Î ÁöÁú, ´ç, ºû ¿¡³ÊÁö, ÆéŸÀ̵å, ´Ü¹éÁú ÇüÅÂÀÇ ¸Þ½ÃÁö ¼ö½Å±â ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷¸·¿¡ Á¸ÀçÇÏ¸ç ¸ðµç »ý¸®Àû °úÁ¤¿¡ °ü¿©ÇÕ´Ï´Ù. ÀÌ ¼ö¿ëü´Â ¿°Áõ¼º Áúȯ, ´ë»ç ÀÌ»ó, ½ÉÀå Áúȯ, ¾Ï, ´Ü¹ß¼º Áúȯ µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú GPCRÀº Æ÷À¯·ù, ½Ä¹°, ¹Ì»ý¹°, ¹«Ã´Ãßµ¿¹°À» Æ÷ÇÔÇÑ ¿©·¯ »ý¹°ÀÇ ¼¼Æ÷¸·¿¡µµ Á¸ÀçÇÕ´Ï´Ù.

G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå µ¿Çâ :

Àü ¼¼°èÀûÀ¸·Î ½Å¾à°³¹ß¿¡ GPCRÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó ¾Ï ȯÀÚ ¼ö Áõ°¡¿Í ½ÉÇ÷°ü °¨¿°, È£Èí°ï¶õ°ú °°Àº »ýÈ°½À°üº´ Áõ°¡·Î ÀÎÇØ ½Å¾à °³¹ß¿¡ GPCRÀÌ ±¤¹üÀ§ÇÏ°Ô È°¿ëµÇ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, GPCRÀº ¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇϱ⠶§¹®¿¡ ´Ù¾çÇÑ È­ÇÐ ¹°Áú°ú »ý¹°ÇÐÀû ¾à¹°·Î Á¶ÀýÇÒ ¼ö ÀÖÀ¸¸ç, ¿©·¯ »ý¸®Àû °úÁ¤¿¡¼­ GPCRÀÇ ±¤¹üÀ§ÇÑ Àû¿ëÀº ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í´Â º°µµ·Î, ÀÚµ¿È­ ¹× Çõ½Å ±â¼úÀ» ÀǾàÇ° °³¹ß ½ºÅ©¸®´× ÀýÂ÷¿¡ ÅëÇÕÇÏ¿© Ä¡·áÁ¦ÀÇ »ý»ê ´É·ÂÀ» Çâ»ó½ÃÅ°´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å¾àÀÇ ¼ö¿ëü ±¸Á¶¿Í Á¦ÇüÈ­¸¦ °£¼ÒÈ­Çϱâ À§ÇÑ °è»êÀû Á¢±Ù¹ýÀÇ ¹ßÀü°ú °°Àº È¿°úÀûÀÎ ½Å¾à °³¹ß ¹æ¹ý·ÐÀÌ Å©°Ô ¹ßÀüÇϸ鼭 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¾¾çÇÐ, ħÀ±, ÀüÀÌ, À¯ÁÖ, Ç÷°ü ÀçÇü¼º µî ¾Ï »ý¹°ÇÐÀÇ ´Ù¾çÇÑ Ãø¸é¿¡¼­ GPCRÀÌ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¾¾ç ÀüÀÌ ¹× Áõ½ÄÀ» Çص¶ÇÏ°í È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ GPCRÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) È°µ¿, ´Ù¾çÇÑ ÀÚµ¿È­ °³¼±, cAMP(cyclic adenosine monophosphate)ÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃ, »ý¸í °øÇÐ ¹× ¹ÙÀÌ¿À ÀǾàÇ° ºÐ¾ß¿¡¼­ ´Ù¾çÇÑ Á¤ºÎ À̴ϼÅƼºêÀÇ ±¸Çö µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • ¼¼°è G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ¿ÔÀ¸¸ç, ÇâÈÄ ¸î ³âµ¿¾È ¾î¶»°Ô ¼ºÀåÇÒ °ÍÀΰ¡?
  • ¼¼°è G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ ¹× ±âȸ´Â ¹«¾ùÀΰ¡?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • °¡Àå ¸Å·ÂÀûÀÎ G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀåÀº ¾î´À ±¹°¡Àΰ¡?
  • Á¦Ç°º° ½ÃÀå ºÐ¼®Àº?
  • ºÐ¼® À¯Çüº° ½ÃÀå ºÐ¼®Àº?
  • ¿ëµµº° ½ÃÀå ºÐ¼®Àº?
  • ¼¼°è G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀå °æÀï ±¸µµ´Â?
  • ¼¼°è G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR) ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå G´Ü¹éÁú ¿¬°á ¼ö¿ëü(GPCR) ¼¼°è ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • ¼¼Æ÷ÁÖ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ŽÁö Å°Æ®
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼¼Æ÷¹è¾ç ½Ã¾à
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¸®°£µå
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼® : ¾î¼¼ÀÌ À¯Çüº°

  • cAMP ±â´É ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Ä®½· ±â´É ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • B-Arrestin ±â´É ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Radioligand Binding ¹× GTP¥ãS ±â´É ¾î¼¼ÀÌ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Internalization Assays
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Trafficking Assays
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ¾Ï ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÁßÃ߽Űæ°è ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ´ë»ç ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½ÉÇ÷°ü ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿°Áõ ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • È£Èí±â ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ij³ª´Ù
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÀϺ»
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Àεµ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Çѱ¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • È£ÁÖ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Àεµ³×½Ã¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • À¯·´
    • µ¶ÀÏ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÇÁ¶û½º
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ¿µ±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÀÌÅ»¸®¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ½ºÆäÀÎ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ·¯½Ã¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ¸ß½ÃÄÚ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ, ±âȸ

  • ½ÃÀå °³¿ä
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abcam plc
    • Becton Dickinson and Company
    • Enzo Biochem Inc.
    • Eurofins DiscoverX Products LLC
    • HD Biosciences Co. Ltd.(WuXi AppTec)
    • Merck KGaA
    • Molecular Devices LLC(Danaher Corporation)
    • PerkinElmer Inc.
    • Promega Corporation
    • Thermo Fisher Scientific Inc.
LSH 24.02.23

Abstract

The global G-protein coupled receptors (GPCRs) market size reached US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.69% during 2024-2032. The increasing adoption of GPCRs in drug discovery, the rising number of cancer cases, and extensive research and development (R&D) activities represent some of the key factors driving the market.

G-protein-coupled receptors (GPCRs) are the largest protein family encoded by the human genome. They are signal-transducing molecules that transmit signals to cells and play a key role in converting an extracellular stimulus into intracellular responses. They are located in the cell membrane and are responsible for all physiological processes. GPCRs are cell surface receptors that act like an inbox for messages in the form of lipids, sugars, light energy, peptides, and proteins. These receptors are widely used in the treatment of various diseases, such as inflammatory disorders, metabolic imbalances, cardiac disorders, cancer, and monogenic disorders. As a result, GPCRs are also found in the cell membranes of several organisms, including mammals, plants, microorganisms, and invertebrates.

G-Protein Coupled Receptors (GPCRs) Market Trends:

The increasing adoption of GPCRs in drug discovery across the globe is one of the key factors driving the market growth. In line with this, the widespread utilization of GPCRs in the development of novel pharmaceuticals due to the rising number of cancer cases and lifestyle-related diseases, such as cardiovascular infections and respiratory difficulties, are favoring the market growth. Moreover, the extensive application of GPCRs in several physiological processes as they can be modulated by a wide range of chemical or biological agents due to their cell-surface location is acting as another growth-inducing factor. Apart from this, the integration of automation and innovative technologies with drug development screening procedures to improve their capabilities in therapeutic production is providing an impetus to the market growth. Furthermore, significant developments in effective drug discovery methods, such as advancements in the computational approaches to streamline receptor structure and formulation of new drugs, are propelling the market growth. Additionally, the widespread adoption of GPCRs in oncology and various aspects of cancer biology, such as invasion, migration, and vascular remolding, is providing a considerable boost to the market growth. Besides this, the increasing utilization of GPCRs for decoding metastasis and growth of tumors and developing effective lines of treatment is positively influencing the market growth. Other factors, including extensive research and development (R&D) activities, various automation improvements, the widespread adoption of cyclic Adenosine Monophosphate (cAMP), and the implementation of various government initiatives in the biotechnology and biopharmaceutical sector are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global G-protein coupled receptors (GPCRs) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, assay type, and application.

Product Insights:

Cell Lines

Detection Kits

Cell Culture Reagents

Ligands

The report has provided a detailed breakup and analysis of the G-protein coupled receptors (GPCRs) market based on the product. This includes cell lines, detection kits, cell culture reagents and ligands. According to the report, cell lines represented the largest segment.

Assay Type Insights:

cAMP Functional Assays

Calcium Functional Assays

B-Arrestin Functional Assays

Radioligand Binding and GTPγS Functional Assays

Internalization Assays

Trafficking Assays

Others

The report has provided a detailed breakup and analysis of the G-protein coupled receptors (GPCRs) market based on the assay type. This includes cAMP functional, calcium functional, B-Arrestin functional, radioligand binding and GTPγS functional, internalization, and trafficking assays. According to the report, cAMP functional assays represented the largest segment.

Application Insights:

Cancer Research

CNS Research

Metabolic Research

Cardiovascular Research

Inflammation Research

Respiratory Research

Others

The report has provided a detailed breakup and analysis of the G-protein coupled receptors (GPCRs) market based on the application. This includes cancer, CNS, metabolic, cardiovascular, inflammation, respiratory research, and others. According to the report, cancer research represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for G-protein coupled receptors (GPCRs). Some of the factors driving the North America G-protein coupled receptors (GPCRs) market included rising number of cancer cases, extensive research and development (R&D) activities, and various automation improvements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global G-protein coupled receptors (GPCRs) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Becton Dickinson and Company, Enzo Biochem Inc., Eurofins DiscoverX Products LLC, HD Biosciences Co. Ltd. (WuXi AppTec), Merck KGaA, Molecular Devices LLC (Danaher Corporation), PerkinElmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., etc.

Key Questions Answered in This Report:

  • How has the global G-protein coupled receptors (GPCRs) market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global G-protein coupled receptors (GPCRs) market?
  • What are the key regional markets?
  • Which countries represent the most attractive G-protein coupled receptors (GPCRs) markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the assay type?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global G-protein coupled receptors (GPCRs) market?
  • Who are the key players/companies in the global G-protein coupled receptors (GPCRs) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global G-Protein Coupled Receptors (GPCRs) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Cell Lines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Detection Kits
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cell Culture Reagents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Ligands
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Assay Type

  • 7.1 cAMP Functional Assays
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Calcium Functional Assays
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 B-Arrestin Functional Assays
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Radioligand Binding and GTPγS Functional Assays
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Internalization Assays
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Trafficking Assays
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Cancer Research
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 CNS Research
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Metabolic Research
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cardiovascular Research
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Inflammation Research
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Respiratory Research
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abcam plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Becton Dickinson and Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Enzo Biochem Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eurofins DiscoverX Products LLC
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 HD Biosciences Co. Ltd. (WuXi AppTec)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck KGaA
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Molecular Devices LLC (Danaher Corporation)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 PerkinElmer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Promega Corporation
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Thermo Fisher Scientific Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦